
Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein



Cat. No.	МНС-НМ422Т
Descriptio	n
Source	Recombinant Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.
	It contains Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVGAVGVGK peptide.
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGAVGVGK
Molecular Weight	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Durit,	> 95% as determined by Bis-Tris PAGE
Purity	> 95% as determined by HPLC
Formulati	on and Storage
Formulatio	n Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Backgrou	nd
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors

and synthetic lethality interactors of KRAS are discussed in detail.

Assay Data



Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein

